June M. McKoy, MD, MPH, JD, MBA
June M. McKoy, MD, MPH, JD, MBA is an emerging expert in pharmacovigilance and pharmacosurveillance, health policy, and cost-effectiveness/comparative effectiveness analyses, particularly in the domain of cancer. Her research is focused on adverse drug reactions among older (>65 years) populations and cancer health disparities research with the focus on improving patient safety for older individuals with cancer. Her work involves the detection and assessment of safety signals related to drugs and devices and the timely dissemination of findings to relevant stakeholders. A related research focus is comparative and cost effectiveness analyses of cancer related therapies targeted at older cancer patients and safe and cost-effective transitions of care for this cohort. Presently, she is engaged in a collaborative NCI sponsored minority biobanking/biospecimen collection initiative with colleagues at several comprehensive cancer centers nationwide. An emerging area of interest involves studies in pharmacogenomics, which are expected to aid in prescribing decisions and will likely predict older cancer patients who will respond appropriately to a given cancer-related medication or experience severe adverse drug reactions. Dr. McKoy serves as Director of Geriatric Oncology for the Robert H. Lurie Comprehensive Cancer Center where she is in the process of developing the Senior Oncology Advocacy and Research Program (SOAR).
Current Research Projects
Adverse Drug Reactions in Geriatric Cancer Patients
The major goals of this continuing project are to improve the completeness and quality of reports and the assignment of causality within the domain of serious adverse cancer drug events for older persons living with cancer. This is expected to enhance pharmaceutical safety among this vulnerable and disparate population.
Role: Principal Investigator
Partnership to End Disparities in Minority Biospecimen/Biobanking: Region 5 BMaP
The major goals of this critical partnership is to create unique, centralized, and public resources for multiethnic biobanking/biospecimens, and to ensure the availability of high-quality human biospecimens for cancer research that examines the cultural differences of diverse communities in specific regions.
U01 CA116875 -9/1/05-8/31/11 (no cost extension)
Chicago Cancer Navigation Project
This patient navigation intervention seeks to (1) increase the proportion of patients with diagnostic evaluations at intervention sites compared with usual care at control sites and past performance; (2) improve mean time to diagnostic resolution between abnormal screening and definitive follow-up; (3) significantly shorten the time to initiation of treatment following confirmatory diagnosis; (4) evaluate cost-effectiveness; (5) identify psychosocial and demographic factors associated with navigation non-adherence; and (6) assess patient satisfaction with the navigation experience. Results are currently being analyzed and manuscripts are being written.
Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood. 2012 Jan 19;119(3):692-5. Epub 2011 Nov 23
Nabhan C, Smith SM, Helenowski I, Ramsdale E, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory S, Evens AM.
Analysis of very elderly (=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. British journal of haematology 2011 Nov 16; :
Lau DT, Jarzebowski MH, McKoy JM. Anticancer drug use in geriatric patients: concerns and challenges. Clinical therapeutics 2011 Oct; 33(10):1408-12
Jean-Pierre P, Fiscella K, Winters PC, Post D, Wells KJ, McKoy JM, Battaglia T, Simon MA, Kilbourn K; The Patient Navigation Research Program Group. Psychometric development and reliability analysis of a patient satisfaction with interpersonal relationship with navigator measure: a multi-site patient navigation research program study. Psychooncology. 2011 Jun 17. doi: 10.1002/pon.2002.
Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, Samaras AT, Boyle SN, Bennett CL, West DP, Guise TA. Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res. 2011 Feb 1;17(3):560-8.
Bennett CL, McKoy JM, Henke M, Silver SM, MacDougall IC, Birgegård G, Luminari S, Casadevall N, Schellekens H, Sartor O, Lai SY, Armitage JO. Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park). 2010 Mar;24(3):260-8
McKoy JM, Samaras AT, Bennett CL. Providing Cancer Care to a Graying and Diverse Cancer Population in the 21st Century: Are We Prepared?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Apr 29.
McKoy JM, Samaras AT, Luu TH, Bennett CL. Upping recruitment in clinical trials: are the costs worth it? Onkologie. 2009 Jul;32(7):378-9. Epub 2009 Jun 20.
McKoy JM, Bolden CR, Samaras A, Raisch DW, Chandler K, Bennett CL. Sildenafil- and tadalafil-associated optic neuropathy: implications for men after prostate cancer treatment. Community Oncol. 2009 Feb 1;6(2):78-80.
McKoy JM, Fitzner KA, Edwards BJ, Alkhatib M, Tigue CC, Nonzee NJ, Bolden CR, Bennett CL. Cost considerations in the management of cancer in the older patient.
Oncology (Williston Park, N.Y.) 2007 Jun; 21(7):851-7; discussion 858, 860, 862 passim